| 1 |
Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? |
|
|
| Amanda Pereira-Salgado,Edmond Michael Kwan,Ben Tran,Peter Gibbs,Johann De Bono,Maarten IJzerman |
|
| European Urology Focus. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer |
|
|
| Robert B. Den,Daniel George,Christopher Pieczonka,Megan McNamara |
|
| American Journal of Clinical Oncology. 2019; 42(4): 399 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond |
|
|
| Simon Linder,Henk G van der Poel,Andries M Bergman,Wilbert Zwart,Stefan Prekovic |
|
| Endocrine-Related Cancer. 2019; : R31 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
ErbB-2 signaling in advanced prostate cancer progression and potential therapy |
|
|
| Dannah R Miller,Matthew A Ingersoll,Ming-Fong Lin |
|
| Endocrine-Related Cancer. 2019; 26(4): R195 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
The Androgen Receptor Splice Variant AR-V7 as a Biomarker of Resistance to Androgen-axis Targeted Therapies in Advanced Prostate Cancer |
|
|
| Tian Zhang,Lawrence I. Karsh,Michael J. Nissenblatt,Steven E. Canfield |
|
| Clinical Genitourinary Cancer. 2019; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology |
|
|
| Darren Ming-Chun Poon,Chi-Kwok Chan,Tim-Wai Chan,Foon-Yiu Cheung,Philip Wai-Kay Kwong,Eric Ka-Chai Lee,Angus Kwong-Chuen Leung,Simon Yiu-Lam Leung,Wai-Kit Ma,Hing-Shing So,Po-Chor Tam,Lap-Yin Ho |
|
| BJU International. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Prostate Tumor Neuroendocrine Differentiation via EMT: The Road Less Traveled |
|
|
| Haley Dicken,Patrick J. Hensley,Natasha Kypriaou |
|
| Asian Journal of Urology. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells |
|
|
| Ariunbold Natsagdorj,Kouji Izumi,Kaoru Hiratsuka,Kazuaki Machioka,Hiroaki Iwamoto,Renato Naito,Tomoyuki Makino,Suguru Kadomoto,Kazuyoshi Shigehara,Yoshifumi Kadono,Wen-Jye Lin,Aerken Maolake,Atsushi Mizokami |
|
| Cancer Science. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
TGF-ß receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer |
|
|
| Channing Paller,Hong Pu,Diane E. Begemann,Cameron A. Wade,Patrick J. Hensley,Natasha Kyprianou |
|
| The Prostate. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance |
|
|
| Lorenzo Bascetta,Arianna Oliviero,Romina D’Aurizio,Monica Evangelista,Alberto Mercatanti,Marco Pellegrini,Francesca Marrocolo,Sergio Bracarda,Milena Rizzo |
|
| International Journal of Molecular Sciences. 2017; 18(7): 1512 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial |
|
|
| Kouji Izumi,Atsushi Mizokami,Mikio Namiki,Shogo Inoue,Nobumichi Tanaka,Yuko Yoshio,Kei Ishibashi,Manabu Kamiyama,Noriyasu Kawai,Hideki Enokida,Takashi Shima,Shizuko Takahara |
|
| BMC Cancer. 2017; 17(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 12 |
Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer |
|
|
| Bryan Hoang,Mark J. Ernsting,Wei-Hsin Sophia Tang,Joseph Bteich,Elijus Undzys,Taira Kiyota,Shyh-Dar Li |
|
| Cancer Letters. 2017; 410: 169 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 13 |
Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis |
|
|
| Mike Fang,Mary Nakazawa,Emmanuel S. Antonarakis,Chun Li |
|
| Prostate Cancer. 2017; 2017: 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 14 |
Mechanisms of Therapeutic Resistance in Prostate Cancer |
|
|
| Mary Nakazawa,Channing Paller,Natasha Kyprianou |
|
| Current Oncology Reports. 2017; 19(2) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 15 |
Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer |
|
|
| Kouji Izumi,Atsushi Mizokami,Hsiu-Ping Lin,Hui-Min Ho,Hiroaki Iwamoto,Aerken Maolake,Ariunbold Natsagdorj,Yasuhide Kitagawa,Yoshifumi Kadono,Hiroshi Miyamoto,Chiung-Kuei Huang,Mikio Namiki,Wen-Jye Lin |
|
| Oncotarget. 2016; 7(7): 8389 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 16 |
Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide |
|
|
| Dominic Pilon,Ajay S. Behl,Lorie A. Ellis,Bruno Emond,Patrick Lefebvre,Nancy A. Dawson |
|
| Journal of Managed Care & Specialty Pharmacy. 2016; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 17 |
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer |
|
|
| Konstantina Skaltsa,Cristina Ivanescu,Shevani Naidoo,De Phung,Stefan Holmstrom,Nicholas R. Latimer |
|
| Targeted Oncology. 2016; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 18 |
Aminomethylphosphonic Acid and Methoxyacetic Acid Induce Apoptosis in Prostate Cancer Cells |
|
|
| Keshab Parajuli,Qiuyang Zhang,Sen Liu,Zongbing You |
|
| International Journal of Molecular Sciences. 2015; 16(5): 11750 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 19 |
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer |
|
|
| Hossein Jadvar,Sudha Challa,David I. Quinn,Peter S. Conti |
|
| Cancer Biotherapy and Radiopharmaceuticals. 2015; 30(5): 195 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 20 |
Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives |
|
|
| Frank dela Rama,Caroline Pratz |
|
| Clinical Journal of Oncology Nursing. 2015; 19(6): 723 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 21 |
Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147–53 |
|
|
| Kevin Lu |
|
| European Urology. 2015; 68(6): e129 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 22 |
Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer |
|
|
| Avishay Sella,Tal Sella,Avivit Peer,Raanan Berger,Stephen Jay Frank,Eli Gez,David Sharide,Henry Hayat,Ekaterina Hanovich,Svetlana Kovel,Eli Rosenbaum,Victoria Neiman,Daniel Keizman |
|
| Clinical Genitourinary Cancer. 2014; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
